SDGR$17.47
$17.7066
Chart
Performance
Key Stats
AI SDGR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuySchrödinger shows a mixed investment profile with strong long-term potential driven by its technology, but current profitability and short-term technicals suggest caution. Investors should monitor earnings performance and cash flow trends.
Thematic
Schrödinger operates at the intersection of software and drug discovery, leveraging advanced computational platforms for significant growth potential in life sciences and materials science. Its focus on novel molecule discovery positions it well for future innovation.
Fundamental
Schrödinger's financials show significant investment in growth, leading to negative earnings and cash flow. While revenue is growing, profitability remains a key concern.
Technical
The stock is trading below key moving averages and exhibits weak momentum, suggesting a bearish short-term outlook. Support levels are being tested, and a sustained uptrend has not yet formed.
| Factor | Score |
|---|---|
| Drug Discovery & Development | 85 |
| Materials Science Applications | 70 |
| Software as a Service (SaaS) | 75 |
| Collaboration & Partnerships | 80 |
| Market Disruption Potential | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 75 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 55 |
| Short-term Performance | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprises
The company has exceeded earnings per share (EPS) estimates in 5 out of the last 6 quarters, with positive surprises ranging from 12.75% to 13.17%.
Undervalued Based on Price-to-Sales
The trailing Price-to-Sales (PS) ratio of 8.2 is lower than the 1-year average of 7.2, suggesting a potential undervaluation relative to historical sales multiples.
Bearish Points (8)
Negative Earnings Trend
The company has reported negative EPS TTM (-2.63) and negative net income in multiple recent periods (e.g., -187.12M in 2024), indicating significant profitability challenges.
High Price-to-Sales Ratio
The Price-to-Sales (PS) ratio of 6.0 (TTM) is considerably higher than the 2024 estimate of 6.0, indicating a potentially overvalued stock relative to its revenue.
Calendar
August 2025
7
Next Earnings Date
H: $-0.68
A: $-0.68
L: $-0.68
H: 54.90M
A: 52.03M
L: 46.73M
Profile
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Seasonals
Price Target
31.78 USD
The 39 analysts offering 1 year price forecasts for SDGR have a max estimate of 39.00 and a min estimate of 26.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor specializing in AI-driven drug discovery, similar to SDGR's focus on accelerating drug development through computational methods.
Weight: 93
A clinical-stage biotechnology company leveraging AI and machine learning to industrialize drug discovery, representing a direct competitor in the computational drug discovery space.
Weight: 90
A biotech company that uses computational and experimental approaches to study protein motion, a core area where Schrödinger's platform provides significant insights and tools.
Weight: 88
An AI-enabled drug discovery company focused on using artificial intelligence to identify novel drug targets and accelerate drug development, a direct peer and competitor to SDGR.